Followers | 59 |
Posts | 2166 |
Boards Moderated | 1 |
Alias Born | 02/18/2014 |
Tuesday, October 03, 2017 8:09:02 AM
By Saul Bowman -
October 3, 2017
Genocea Biosciences, Inc. (GNCA) belonging to the Healthcare sector has declined -2.05% and closed its last trading session at $1.43.
The company reported its EPS on 6/29/2017. Currently, the stock has a 1 Year Price Target of $10.63.
The consensus recommendation, according to Zacks Investment research, is 2. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell.
The Stock had a 1.25 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 1.25 and 1.5 respectively.
Genocea Biosciences, Inc. on 6/29/2017 reported its EPS as $-0.45 with the analysts projecting the EPS of the stock as $-0.44. The company beat the analyst EPS Estimate with the difference of $-0.01. This shows a surprise factor of -0.023%.
Many analysts have provided their estimated foresights on Genocea Biosciences, Inc. Earnings, with 4 analysts believing the company would generate an Average Estimate of $-0.52.
Whereas they predicted High and Low Earnings Estimate as $-0.48 and $-0.57 respectively. While in the same Quarter Previous year, the Actual EPS was $-0.45.
For the Current Quarter, the growth estimate for Genocea Biosciences, Inc. is -15.6%, while for the Next Quarter the stock growth estimate is 33.9%.
Insider Trades for Genocea Biosciences, Inc. show that the latest trade was made on 23 Jul 2017 where Poole Jonathan, the Chief Financial Officer completed a transaction type “Buy” in which 45000 shares were traded at a price of $3.09.
Genocea Biosciences, Inc. (GNCA) has the market capitalization of $40.81 Million. The company rocked its 52-Week High of $7.29 and touched its 52-Week Low of $1.13.
The stock has Return on Assets (ROA) of -92.3 percent. Return on Equity (ROE) stands at -146.4% and Return on Investment (ROI) of -77.3 percent.
The stock is currently showing YTD performance of -65.29 Percent. The company has Beta Value of 2.06 and ATR value of 0.44. The Weekly and Monthly Volatility stands at 27.61% and 10.04%.
https://factsreporter.com/2017/10/03/eps-growth-overview-of-genocea-biosciences-inc-gnca/
All Posts About Stock Performance Are Of My Own Opinion!
Click Here For Bounce Plays!!!
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM